Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026 Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 million Q3 revenue, and advances Phase 3 selinexor trial.
These stocks that are showing activity before the opening bell on Wednesday. Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Top movers analysis in the middle of the day on 2025-08-15: top gainers and losers in today's session. Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
What's going on in today's session Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Here are the top movers in Wednesday's session. Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Traders are paying attention to the gapping stocks in Wednesday's session. There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.
KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Beats Revenue for Q2 2024 KPTI stock results show that Karyopharm Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
